Snapshot
Baxter International Inc reported $2.83B of revenue in Q3 2025, up 5.0% year over year, with diluted EPS of $-0.09 and an operating margin of 6.1%.
- Revenue
- $2.83B
- YoY growth
- +5.0%
- Diluted EPS
- $-0.09
- Operating margin
- 6.1%
$2.83B
Revenue
+5.0%
YoY growth
$-0.09
Diluted EPS
6.1%
Operating margin
01 Key takeaways
What management said
- •Today we'll discuss Baxter's third quarter 2025 results along with an update to our full year 2025 outlook and newly issued fourth quarter 2025 guidance.
- •This morning, a press release was issued with our preliminary earnings results and updated outlook.
- •I am pleased to be here for my first earnings call as CEO and look forward to getting to know everyone here better as the quarters progress.
- •This is a business whose portfolio has proven resilient over its almost 100 year history, one that has delivered significant revenues and attractive operating margins and generated solid cash flow over the years.
- •These results reflect challenges in two divisions, the Infusion Therapies and Technologies division within the Medical Products & Therapies segment and the Injectables and Anesthesia division within the Pharmaceuticals segment.
- •Of course, there have been challenges in certain areas that have hampered growth and consistent execution, and we expect our growth algorithm to continue to be pressured in the near-term.
- •The Spectrum IQ LVP now operates on a shared gateway with Novum IQ Syringe, creating a cohesive user experience and is built for the future with EMR interoperability, enhanced software, and innovative analytical capabilities.
- •It is from the basis of a strong balance sheet that we will be better able to invest in the business, support innovation, and deliver and return increased value to our shareholders.
- •This means focusing on improved cash flow and taking a consistent approach to our capital allocation objective.
- •It is in this context that we and the Board intend to reduce the quarterly dividend to $0.01 per share, beginning with the dividend to be paid in January 2026.
- •Earlier this month we rolled out Baxter GPS, our new growth and performance system aimed at driving continuous improvement and a growth and performance mindset.
- •On the bottom line, total company adjusted earnings from continuing operations were $0.69 per share.
SourcesCompany financials · earnings call
Last updated